Physician profile
Sally E Sondergaard
NPI 1275534299
$4,793.30
in general payments reported to CMS, 2019-2025
31 companies · $71.81 in 2025
The $71.81 reported for 2025 was less than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $689 · 2020: $629 · 2021: $881 · 2022: $969 · 2023: $811 · 2024: $742 · 2025: $71.81.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,580 · Education: $44.34.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,580.39 |
| Education | $44.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $604.96 | 2019-2023 | Lo Loestrin Fe, Orilissa, Liletta |
| Astellas Pharma US INC | $539.75 | 2022-2025 | Veozah, Myrbetriq |
| Therapeuticsmd, INC. | $436.67 | 2019-2022 | |
| Exeltis, USA INC. | $359.86 | 2020-2024 | Slynd, Solosec |
| Pfizer INC. | $341.23 | 2019-2024 | |
| Mayne Pharma Commercial LLC | $262.59 | 2021-2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $262.54 | 2019-2024 | |
| Coopersurgical, INC. | $222.25 | 2019-2024 | Paragard T 380a, Paragard T 380a |
| Aspira Women'S Health INC | $208.46 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $162.96 | 2019-2023 | Gardasil 9 |
| Evofem Biosciences, INC. | $151.60 | 2020-2024 | Phexxi |
| Amgen INC. | $150.25 | 2020-2024 | Evenity, Prolia |
| Millicent US INC | $134.81 | 2019-2024 | Femring, Intrarosa |
| Amag Pharmaceuticals, INC. | $117.72 | 2019-2020 | |
| Myovant Sciences INC. | $84.73 | 2021-2022 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Duchesnay USA Incorporated | $84.27 | 2019-2020 | |
| Avion Pharmaceuticals | $79.29 | 2019-2022 | |
| Allergan, INC. | $79.16 | 2019-2020 | |
| Mylan Pharmaceuticals INC. | $78.96 | 2021-2022 | |
| Shield Therapeutics INC | $74.55 | 2024 | |
| Sage Therapeutics, LLC | $72.37 | 2022-2024 | |
| Dysis Medical, INC. | $62.21 | 2019 | |
| Hologic Sales and Service, LLC | $57.84 | 2019-2024 | Aptima |
| Lupin INC. | $32.12 | 2019-2020 | |
| Scynexis, INC. | $28.07 | 2021 | |
| Optumhealth Care Solutions, LLC | $22.72 | 2024 | Vivify Health Care Team Portal 001, Eitan Medical |
| Medtronic, INC. | $19.77 | 2024 | Ligasure |
| Organon LLC | $18.59 | 2021 | |
| Mycovia Pharmaceuticals, INC. | $15.75 | 2023 | Vivjoa |
| Agile Therapeutics, INC. | $14.44 | 2021 | |
| Minerva Surgical, INC | $12.81 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sally Sondergaard listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.